Key result
A clustered model of CD142+/CD61+/AV+, CD45+/AV+ and CD146+/AV+ circulating microparticles predicted future cardiovascular events (AUC 0.805; 95% CI 0.672-0.938; p<0.0001).
Why the study?
Do circulating microparticles (CD142+/CD61+, CD146+, CD45+) predict cardiovascular events in high-risk asymptomatic patients on a Mediterranean diet supplemented with nuts?
Case-Control (n=50)
Do circulating microparticles (CD142+/CD61+, CD146+, CD45+) predict cardiovascular events in high-risk asymptomatic patients on a Mediterranean diet supplemented with nuts?
Effect estimate: AUC 0.805 (95% CI 0.672 to 0.938)
p-value: p=<0.0001
Reduced circulating microparticles derived from activated platelets, leukocytes, and endothelial cells predict protection against cardiovascular events in high-risk patients on a Mediterranean diet supplemented with nuts.
May aid risk stratification in high-risk patients; hypothesis-generating pending prospective validation.
Circulating microparticles (cMPs) are small phospholipid-rich microvesicles shed by activated cells that play a pivotal role in cell signalling related to the pathogenesis of atherothrombosis. We aimed to investigate the prognostic value of cMPs released from different vascular cells for cardiovascular event (CVE) presentation in asymptomatic patients at high cardiovascular risk factors under nutritional and pharmacologic treatment. This is a nested case-control study of 50 patients from the five-year follow-up prospective PREDIMED trial enrolled in the nuts arm of the Mediterranean diet (MedDiet-nuts). We randomly selected 25 patients who had suffered a CVE during follow-up and pair-matched them for sex, age, and classical CV risk factors to 25 patients who remained asymptomatic (no-CVE). Total Annexin V-(AV)+ cMPs and cMPs from cells of the vascular compartment were quantified by flow cytometry at baseline and after one year follow-up. MedDiet-nuts and pharmacological treatment neither modified levels nor source of MP shedding in CVE patients. However, no-CVE patients showed 40-86 % decreased total AV+, PAC-1+/AV+, CD61+/AV+, CD142+/CD61+/AV+, CD62P+/AV+, CD146+/AV+, CD63+/AV+ and CD11a+/AV+ cMPs at one year follow-up (p≤0.046, all). CD142+/CD61+/AV+, CD146+/AV+ and CD45+/AV+ cMPs were decreased in no-CVE patients compared to CVE patients. A ROC-curve clustered model for CD142+/CD61+/AV+, CD45+/AV+ and CD146+/AV+ cMPs predicted a future CVE [p<0.0001, AUC=0.805 (0.672 to 0.938)]. In patients at high CV risk profile treated with a controlled MedDiet supplemented with nuts and receiving up-to-date CV drug treatment, reduced cMPs derived from activated platelets, leukocytes and endothelial cells are predictive of protection against CVE within the next four years.
No takes yet. Share an insight, caveat, or question.
Chiva‐Blanch et al. (2016) conducted a case-control in High cardiovascular risk (n=50). Circulating microparticles (cMPs) vs. Patients who remained asymptomatic was evaluated on Future cardiovascular event (CVE) (AUC 0.805, 95% CI 0.672 to 0.938, p=<0.0001). A clustered model of CD142+/CD61+/AV+, CD45+/AV+ and CD146+/AV+ circulating microparticles predicted future cardiovascular events (AUC 0.805; 95% CI 0.672-0.938; p<0.0001).